Voyager Therapeutics Inc (NDAQ:VYGR) had its price objective increased by Chardan Capital from $11.00 to $13.00 in a research note published on Thursday morning. Chardan Capital currently has a neutral rating on the stock.
Separately, Instinet initiated coverage on Voyager Therapeutics in a report on Thursday, March 2nd. They issued a buy rating and a $31.00 price target for the company.
Shares of Voyager Therapeutics (NDAQ:VYGR) opened at 10.91 on Thursday. Voyager Therapeutics has a 52 week low of $8.30 and a 52 week high of $18.25. The stock’s 50 day moving average is $12.34 and its 200-day moving average is $12.64. The firm’s market cap is $291.52 million.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.